Compare Bristol-Myers Squibb Co (BMY) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vanguard Real Estate Index Fund ETF — how do they compare? Bristol-Myers Squibb Co trades at $58.83 (market cap $116.30B), while Vanguard Real Estate Index Fund ETF trades at $98.31. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Vanguard Real Estate Index Fund ETF pays none, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, Bristol-Myers Squibb Co nearer its low. Which is the better fit depends on your goals.
| BMY | VNQ | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $98.66 |
52-Week Low | $42.60 | $87.00 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
VNQ (Vanguard Real Estate ETF) trades at $97.87, up 0.57% today, with a bullish technical signal from moving averages. The ETF shows strong momentum in the real estate sector, benefiting from AI-driven data center REIT performance. Recent news highlights REITs outpacing the broader market despite interest rate pressures, with VNQ being the default choice for real estate exposure.
The outlook for VNQ remains positive as real estate fundamentals strengthen, with dividends rising and M&A activity intensifying. Key risks include persistent high interest rates and inflation volatility. Wall Street sentiment is cautiously optimistic, focusing on durable income streams and sector recovery potential amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
